Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients
The purpose of this study is to examine the efficacy and safety of gefitinib combinated with Pemetrexed/Cisplatin in advanced non-small cell lung cancer (NSCLC).
Toxicity|Non-small Cell Lung Cancer
DRUG: Gefitinib|DRUG: Pemetrexed|DRUG: Cisplatin or carboplatin
response rate, six weeks
Number of Participants with Adverse Events, according to NCI CTC V3.0, six weeks|Progression free survival, six weeks|quality of life, according to FACT-LCS scores, six weeks
The purpose of this study is to examine the efficacy and safety of gefitinib combinated with Pemetrexed/Cisplatin in advanced non-small cell lung cancer (NSCLC).